According to the Centers for Disease Control (CDC), there are thirteen OACs: adenocarcinoma of the esophagus, post-menopausal breast cancer, colorectal cancer, uterine cancer, gallbladder cancer, upper stomach cancer, kidney cancer, ovarian cancer, pancreatic cancer, thyroid cancer, meningioma, and multiple myeloma
The top opportunities in the GLP-1 receptor agonist markets segmented by route of administration will arise in the parenteral segment, which will gain $47,566.5 million of global annual sales by 2030
Psychiatry 18, 595606
Seiwerth S, Brcic L, Vuletic L, Kolenc D, Aralica G, Misic M, et al
Rather, it highlights the reality that healthcare providers are balancing multiple risks and benefits when helping patients make treatment decisions